Core Viewpoint - The collaboration between the company and Eli Lilly marks another significant licensing deal worth over $8.85 billion, reinforcing the strength of the company's antibody technology platform [1] Group 1: Collaboration Details - The company has entered into a strategic partnership with Eli Lilly to advance global R&D of innovative drugs in oncology and immunology [1] - The agreement includes an upfront payment of $350 million, potential milestone payments of up to $8.5 billion, and a tiered sales revenue sharing structure [1] - The company retains all rights in Greater China while Eli Lilly obtains exclusive global development and commercialization rights outside this region [1] Group 2: Financial Projections and Growth - The company anticipates a revenue growth of approximately 45% year-on-year in 2025, reaching around 11.9 billion RMB, with Q4 2025 expected to generate about 3.3 billion RMB [2] - The product pipeline, including IBI363, IBI343, and IBI324, is projected to drive significant revenue growth, with a combined potential market space exceeding $60 billion [2] - Management expects to generate 8-10 new molecules annually from its early-stage clinical pipeline starting in 2026, aiming to push five products into global Phase III trials by 2030 [2] Group 3: Target Price and Ratings - The target price is maintained at HKD 105, reflecting the potential contributions from the Eli Lilly collaboration and adjustments based on the latest management guidance regarding the Takeda collaboration [3]